All Trials

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic or unresectable salivary gland carcinoma (any histology, including adenoid cystic), ECOG 0–1, measurable non-CNS disease, and no prior PD‑1 or VEGFR TKI therapy receive ivonescimab every 21 days; treated/stable brain metastases allowed. Ivonescimab is a bispecific tetravalent antibody targeting PD‑1 and VEGF to combine immune checkpoint blockade with anti‑angiogenesis.

ClinicalTrials.gov ID: NCT06805617

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1 CPS ≥1 recurrent or metastatic HNSCC (oral cavity, oropharynx, hypopharynx, larynx) without prior systemic therapy for incurable disease are randomized to petosemtamab plus pembrolizumab vs pembrolizumab alone. Petosemtamab (MCLA-158) is a bispecific IgG1 targeting EGFR and LGR5 that blocks EGFR signaling and promotes EGFR internalization in LGR5+ tumor cells with Fc-mediated ADCC/ADCP.

ClinicalTrials.gov ID: NCT06525220

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic melanoma (including mucosal/unknown primary; treatment-naïve allowed) or recurrent/metastatic HNSCC after platinum therapy are randomized to pembrolizumab plus GB1211 vs pembrolizumab plus placebo. GB1211 (selvigaltin) is an oral selective galectin‑3 inhibitor aimed at reversing immune suppression and resistance to PD‑1 blockade; prior PD‑1/PD‑L1 allowed if ≥6 months since last dose with progression; key exclusions include active autoimmune disease and untreated brain mets.

ClinicalTrials.gov ID: NCT05913388

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: First-line study for adults with recurrent/metastatic, non-nasopharyngeal HNSCC (ECOG 0–1, measurable disease, no prior PD-1/TIGIT; prior curative-intent platinum allowed if relapse >6 months) comparing zimberelimab (anti–PD-1) plus carboplatin/paclitaxel with or without domvanalimab, an Fc-silent anti-TIGIT antibody that augments T-cell activity. Aims to determine whether adding anti-TIGIT to PD-1 blockade and platinum-taxane chemotherapy improves ORR and PFS.

ClinicalTrials.gov ID: NCT06727565

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic HPV-negative HNSCC after prior PD-1/PD-L1 inhibitor and platinum therapy (ECOG 0–1) are randomized to cetuximab plus ficlatuzumab vs cetuximab plus placebo. Ficlatuzumab is an anti-HGF monoclonal antibody that blocks HGF/MET signaling; prior EGFR inhibitor in the R/M setting is excluded.

ClinicalTrials.gov ID: NCT06064877

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with RAF dimer–driven thyroid cancers: RAIR differentiated (papillary/follicular/Hürthle cell/poorly differentiated) with recent progression or anaplastic, harboring RAS or NF1 mutations, RET/NTRK/ALK fusions, or non‑V600E/K/class 2–3 BRAF alterations; ECOG 0–1, measurable disease, any prior lines, but no prior MEK/class II–III BRAF/FAK inhibitors. Treatment is oral avutometinib (dual RAF/MEK clamp) plus defactinib (FAK/Pyk2 inhibitor) on a 3-weeks-on/1-week-off schedule, with ORR as the primary endpoint.

ClinicalTrials.gov ID: NCT06007924

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1 CPS ≥1 recurrent or metastatic HNSCC (oral cavity, hypopharynx, larynx, or HPV-negative oropharynx), no prior systemic therapy for R/M disease, are randomized to pembrolizumab plus ficerafusp alfa (BCA101) vs pembrolizumab plus placebo. Ficerafusp alfa is a tumor-targeted bifunctional IgG1 that inhibits EGFR and locally traps TGF-β to enhance antitumor immunity; exclusions include active CNS mets, recent ICI, prior anti–TGF-β, most prior anti-EGFR mAbs, and autoimmune disease requiring systemic therapy.

ClinicalTrials.gov ID: NCT06788990

A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic or recurrent, non-curable HNSCC (oral cavity, oropharynx, hypopharynx, larynx) who progressed after anti–PD-1 and platinum therapy (ECOG 0–1, measurable disease) are randomized to petosemtamab (MCLA-158), a bispecific EGFR/LGR5 antibody that blocks EGFR signaling and promotes LGR5-mediated EGFR degradation with Fc effector activity, versus investigator’s choice single-agent therapy. Key endpoints are ORR and OS; excludes nasopharyngeal primaries and active CNS disease.

ClinicalTrials.gov ID: NCT06496178

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of zanzalintinib (XL092), an oral multikinase inhibitor of VEGFR2, MET, and TAM (TYRO3/AXL/MER), as first-line systemic therapy in adults with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (papillary, follicular, oncocytic/Hürthle, or poorly differentiated) with RECIST-measurable disease and recent progression. Excludes prior systemic therapy in the RAI-refractory setting and patients with active brain mets or significant cardiovascular/GI risk; daily dosing in 21-day cycles until progression or toxicity.

ClinicalTrials.gov ID: NCT06959641

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Newly diagnosed, high-grade non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB/C–IV) eligible for neoadjuvant chemo and interval debulking; excludes low-grade, clear cell, mucinous, prior therapy, and planned bevacizumab. Compares standard neoadjuvant/adjuvant carboplatin-paclitaxel (with SOC maintenance allowed) versus the same plus intraperitoneal IMNN-001, a DNA-mediated IL-12 immunotherapy designed for local IL-12 expression to enhance IFN-γ/NK/CD8+ activity and reduce peritoneal immunosuppression.

ClinicalTrials.gov ID: NCT06915025